Intellia Therapeutics annual revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Intellia Therapeutics Revenue Growth & History (NTLA)
Intellia Therapeutics reported $67.7M in revenue for fiscal 2025, an increase of 16.92% from the previous fiscal year.
View full Intellia Therapeutics company overviewIntellia Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $67.7M | $9.8M | +16.92% |
| 2024 | 2024-12-31 | $57.9M | $21.6M | +59.55% |
| 2023 | 2023-12-31 | $36.3M | −$15.8M | −30.40% |
| 2022 | 2022-12-31 | $52.1M | $19.1M | +57.69% |
| 2021 | 2021-12-31 | $33.1M | −$24.9M | −43.01% |
| 2020 | 2020-12-31 | $58.0M | $14.9M | +34.55% |
| 2019 | 2019-12-31 | $43.1M | $12.7M | +41.63% |
| 2018 | 2018-12-31 | $30.4M | $4.3M | +16.53% |
| 2017 | 2017-12-31 | $26.1M | $9.6M | +58.49% |
| 2016 | 2016-12-31 | $16.5M | — | — |
Intellia Therapeutics quarterly revenue
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.7M | −$6.6M | −46.23% |
| Q1 2026 | 2026-03-31 | $15.0M | −$1.6M | −9.50% |
| Q4 2025 | 2025-12-31 | $23.0M | $10.1M | +78.79% |
| Q3 2025 | 2025-09-30 | $13.8M | $4.7M | +51.27% |
| Q2 2025 | 2025-06-30 | $14.2M | $7.3M | +104.76% |
| Q1 2025 | 2025-03-31 | $16.6M | −$12.3M | −42.54% |
| Q4 2024 | 2024-12-31 | $12.9M | $14.8M | +771.57% |
| Q3 2024 | 2024-09-30 | $9.1M | −$2.9M | −24.02% |
| Q2 2024 | 2024-06-30 | $7.0M | −$6.6M | −48.82% |
| Q1 2024 | 2024-03-31 | $28.9M | $16.3M | +129.53% |
| Q4 2023 | 2023-12-31 | −$1.9M | −$15.5M | −114.12% |
| Q3 2023 | 2023-09-30 | $12.0M | −$1.3M | −9.60% |
| Q2 2023 | 2023-06-30 | $13.6M | −$436,000 | −3.11% |
| Q1 2023 | 2023-03-31 | $12.6M | $1.4M | +12.03% |
| Q4 2022 | 2022-12-31 | $13.6M | $719,000 | +5.59% |
| Q3 2022 | 2022-09-30 | $13.3M | $6.1M | +84.15% |
| Q2 2022 | 2022-06-30 | $14.0M | $7.5M | +114.20% |
| Q1 2022 | 2022-03-31 | $11.3M | $4.8M | +74.58% |
| Q4 2021 | 2021-12-31 | $12.9M | $6.3M | +94.91% |
| Q3 2021 | 2021-09-30 | $7.2M | −$15.0M | −67.58% |
| Q2 2021 | 2021-06-30 | $6.5M | −$9.7M | −59.72% |
| Q1 2021 | 2021-03-31 | $6.4M | −$6.5M | −50.10% |
| Q4 2020 | 2020-12-31 | $6.6M | −$4.3M | −39.69% |
| Q3 2020 | 2020-09-30 | $22.2M | $11.6M | +109.31% |
| Q2 2020 | 2020-06-30 | $16.3M | $5.1M | +46.28% |
| Q1 2020 | 2020-03-31 | $12.9M | $2.5M | +23.80% |
| Q4 2019 | 2019-12-31 | $10.9M | $3.1M | +38.78% |
| Q3 2019 | 2019-09-30 | $10.6M | $3.2M | +43.30% |
| Q2 2019 | 2019-06-30 | $11.1M | $3.4M | +44.82% |
| Q1 2019 | 2019-03-31 | $10.4M | $3.0M | +39.68% |
| Q4 2018 | 2018-12-31 | $7.9M | $1.2M | +18.18% |
| Q3 2018 | 2018-09-30 | $7.4M | $91,000 | +1.24% |
| Q2 2018 | 2018-06-30 | $7.7M | $1.8M | +29.74% |
| Q1 2018 | 2018-03-31 | $7.5M | $1.3M | +20.18% |
| Q4 2017 | 2017-12-31 | $6.7M | — | — |
| Q3 2017 | 2017-09-30 | $7.3M | — | — |
| Q2 2017 | 2017-06-30 | $5.9M | — | — |
| Q1 2017 | 2017-03-31 | $6.2M | — | — |
Intellia Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue grew from $58.0M to $67.7M, a compound annual growth rate of 3.13%. Intellia Therapeutics's latest reported quarter, Q2 2026, generated $7.7M in revenue, a decrease of 46.23% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Intellia Therapeutics source filings ↗